Thioredoxin-Interacting Protein (TXNIP) with Focus on Brain and Neurodegenerative Diseases. by TSUBAKI Haruka et al.
Thioredoxin-Interacting Protein (TXNIP) with
Focus on Brain and Neurodegenerative Diseases.











This is an open access article distributed under the Creative Commons Attribution License which permits
unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited 
 International Journal of 
Molecular Sciences
Review
Thioredoxin-Interacting Protein (TXNIP) with Focus
on Brain and Neurodegenerative Diseases
Haruka Tsubaki , Ikuo Tooyama and Douglas Gordon Walker *
Molecular Neuroscience Research Center, Shiga University of Medical Science, Seta-Tsukinowa,
Otsu 525-0072, Shiga, Japan; ds111857@g.shiga-med.ac.jp (H.T.); kinchan@belle.shiga-med.ac.jp (I.T.)
* Correspondence: walker@belle.shiga-med.ac.jp; Tel.: +81-80-3113-7049
Received: 11 November 2020; Accepted: 3 December 2020; Published: 8 December 2020


Abstract: The development of new therapeutic approaches to diseases relies on the identification of
key molecular targets involved in amplifying disease processes. One such molecule is thioredoxin-
interacting protein (TXNIP), also designated thioredoxin-binding protein-2 (TBP-2), a member of the
α-arrestin family of proteins and a central regulator of glucose and lipid metabolism, involved in
diabetes-associated vascular endothelial dysfunction and inflammation. TXNIP sequesters reduced
thioredoxin (TRX), inhibiting its function, resulting in increased oxidative stress. Many different
cellular stress factors regulate TXNIP expression, including high glucose, endoplasmic reticulum
stress, free radicals, hypoxia, nitric oxide, insulin, and adenosine-containing molecules. TXNIP is
also directly involved in inflammatory activation through its interaction with the nucleotide-binding
domain, leucine-rich-containing family, and pyrin domain-containing-3 (NLRP3) inflammasome
complex. Neurodegenerative diseases such as Alzheimer’s disease have significant pathologies
associated with increased oxidative stress, inflammation, and vascular dysfunctions. In addition,
as dysfunctions in glucose and cellular metabolism have been associated with such brain diseases,
a role for TXNIP in neurodegeneration has actively been investigated. In this review, we will focus on
the current state of the understanding of possible normal and pathological functions of TXNIP in the
central nervous system from studies of in vitro neural cells and the brains of humans and experimental
animals with reference to other studies. As TXNIP can be expressed by neurons, microglia, astrocytes,
and endothelial cells, a complex pattern of regulation and function in the brain is suggested. We will
examine data suggesting TXNIP as a therapeutic target for neurodegenerative diseases where further
research is needed.
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1. Introduction
Oxidative stress resulting from an imbalance in cellular redox can occur due to the production
of excessive levels of reactive oxygen species (ROS) and/or a deficit of cellular antioxidant systems.
Supplementation with various classes of antioxidants has been widely investigated for neurodegenerative
diseases (for recent reviews, see [1,2]). Excess levels of ROS can occur from inflammatory responses by
innate immune cells (e.g., neutrophils, monocytes/macrophages/microglia) due to infections or chronic
autoimmune responses [2], deficiencies in mitochondrial oxidative phosphorylation pathways [3,4],
and environmental factors such as UV light, toxic chemicals, or heavy metals. Oxidative stress is linked
to many different chronic human diseases, particularly those with inflammatory and/or metabolic
components (e.g., diabetes and diabetes-related retinopathy [5], stroke [6], cancers [7], vascular diseases,
and neurodegenerative diseases [8,9]). Developing effective therapies for these diseases requires the
identification of key pathological targets responsible for amplifying disease processes.
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Thioredoxin-interacting protein (TXNIP) has emerged as a key pathological regulator of diseases,
particularly those associated with glucose and lipid abnormalities and inflammation. TXNIP has
been identified in disease mechanisms involved in various cancers [10–12], diabetes mellitus [13],
cardiovascular disease [14], renal disease [15], and retinal disease [16], among others. Many of these
diseases associated with TXNIP can arise from vascular complications of diabetes [17]. The involvement
of TXNIP in diabetes, pancreatic beta-cell death, and glucose metabolism has been the focus of several
recent review articles [14,17,18]. TXNIP was identified (and named) due to its interaction and inhibition
of the key antioxidant proteins thioredoxin-1 (TRX1) and thioredoxin-2 (TRX2) [19–21], but more
recent findings identified properties involved in cellular metabolism and transcription regulation [22],
apoptosis and cell death [13], inflammation [23], and tumor suppression [11,24] that might not be
directly related to the modulation of TRX and oxidative stress.
In this review, we will consider the known features of TXNIP expression with a particular focus
on human and animal brains and different types of neural cells. Particular consideration will be
on how TXNIP and the TRX system may be involved in the pathological features of Alzheimer’s
disease (AD), a chronic neurodegenerative disease of elderly people, which have been associated with
abnormalities in cellular glucose metabolism, mitochondrial dysfunction, inflammation, and oxidative
stress, among others [25]. TXNIP might be an important hub coordinator of different pathological
processes in this disease, but there has been only one published study on its expression and distribution
in human AD brains, and further studies are needed [26]. We will also consider the evidence for the
pathological contribution of diabetes and diabetes-induced oxidative stress to Alzheimer’s disease
(AD) as part of this review [27], and how it can be linked to TXNIP.
2. Biochemistry of TXNIP: Overview
The gene for TXNIP is located on the human chromosome 1q21.1 and is transcribed to four
messenger RNA (mRNA) splice variants [28]. TXNIP is a member of the α-arrestin protein family and
has two arrestin-like domains: one is a PxxP sequence and the other is a PPxY sequence. One mRNA
for TXNIP codes for 336 amino acids for a polypeptide of approximately 37.4 kDa, whereas another
codes for 391 amino acids for a polypeptide of approximately 43.7 kDa. The two other splice variants
have not been associated with proteins. Reported molecular weights of TXNIP vary depending on the
expressing cell type, but the major protein band(s) detected by SDS-gel electrophoresis is/are 50–55 kDa.
This would suggest a certain amount of post-translational modification occurring. Protein bands of
approximately 37 kDa have been observed on immunoblots with certain antibodies and cell types,
but 50–55 kDa polypeptides appear to be the major form. TXNIP was identified initially by several
investigators as vitamin D3-upregulated protein-1 (VDUP1) in different cell types [19–21]. Interestingly,
other studies have not confirmed TXNIP induction by vitamin D3 in additional cell types, and noticeably,
there is a lack of a vitamin D3-responsive element in the TXNIP gene promoter [29,30]. It has been
suggested that vitamin D3 stabilizes cellular TXNIP protein rather than inducing expression [29].
2.1. TXNIP and Thioredoxin System
Earlier studies provided the first link between VDUP1/TXNIP and oxidative stress by
demonstrating binding to reduced, but not oxidized, thioredoxin (TRX) [19–21]. TXNIP can bind
two cysteine residues (Cys32 and Cys35) present in the active catalytic site of TRX. The binding of
oxidized TXNIP to reduced TRX involves the formation of disulfide bonds between TXNIP-Cys247
and TRX-Cys32 [31]. A mutation in TXNIP-Cys247 is sufficient to remove its ability to sequester TRX
activity [31]. Although classified as belonging to the α-arrestin family, these cysteine residues are
unique to TXNIP. TXNIP can bind and inactivate both TRX1 and TRX2 [19,32]. The TRX cellular
disulfide oxidoreductase system is a highly conserved system found from prokaryotes to plants to
mammals [33–35]. TRX plays a central role in protecting cells from oxidative stress. Oxidized TRX is
reduced by NADPH through a reaction catalyzed by thioredoxin reductase complex (TRX-R). Reduced
TRX can then directly reduce disulfides in target proteins [33]. The main form of TRX is TRX1, which is
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located primarily in the cytosol but can be translocated to the plasma membrane and/or nucleus,
particularly under inflammatory conditions [36,37]. Closely related in structure, TRX2 is specific to
mitochondria [38,39]. Immunohistochemistry and in situ hybridization mRNA studies have shown
that TRX was highly expressed in mammalian brains, particularly in subsets of neurons in areas of
high metabolic activity and oxidative burden [40–42]. TRX mRNA expression was highest in the
piliform cortex, dentate gyrus, CA3/CA4 region of the hippocampus, locus coeruleus, and nucleus of
the hypothalamus and solitary tract [41]. Trx2 mRNA and protein were highly expressed in rat brains
in neurons in the olfactory bulb, frontal cortex, hippocampus, some hypothalamic and thalamic nuclei,
cerebellum, and numerous brainstem nuclei [42].
The significance of the TRX system for maintaining cellular health was demonstrated in transgenic
mice overexpressing forms of TRX. Increased expression of human TRX in mice resulted in resistance
to oxidative stress and increased lifespan [43]. Other studies have shown that TRX overexpression in
transgenic mice was protective of transient ischemic brain damage [44]. This effect was also observed
by intravenous administration of TRX protein [45]. These examples of the beneficial outcomes of
increased TRX are used to introduce the widely appreciated pathological consequences of reduced
TRX activity. The first study linking TRX to AD showed a significant reduction in TRX protein levels
in most brain regions in AD cases compared to nondemented controls with accompanying increased
TRX-R activity. This study also demonstrated the protective effect of TRX when added to cultures of
neurons treated with toxic doses of amyloid beta (Aβ) peptide [46]. A further study showed that TRX1
levels were increased significantly in the cerebrospinal fluid (CSF) and plasma of AD cases compared
to mild cognitive impairment (MCI) cases [47]. This suggested that TRX1 was being secreted from
damaged neurons in AD brains. A noticeable alteration in the patterns of TRX1 and TRX2 cellular
immunoreactivity in hippocampal neurons of AD cases was also observed.
2.2. TXNIP Interacting Proteins
TXNIP has been shown to interact with other proteins besides TRX, including importin-α1 [48],
human ecdysoneless (hEcd) [49], and NOD-, LRR-, and pyrin domain-containing protein-3 (NLRP3),
a component of the inflammasome complex [23,50]. These interactions relate to additional identified
properties of TXNIP. The significance of the interaction of TXNIP with inflammasome components and
enhancement of inflammation will be considered.
3. Regulation of TXNIP Expression
Many different cellular stress factors positively or negatively regulate TXNIP expression.
These include UV light, heat shock [51], hypoxia, ROS, nitric oxide [52], nicotinamide adenine
dinucleotide [53], ATP, glutamine, nicotine, vascular endothelial growth factor, basic fibroblast growth
factor [54], transforming growth factor β [55], estradiol [56], calcium channel blockers [57], activators
of advanced glycation endoproduct receptor (RAGE) [58], insulin, and glucose [59]. Activation of
the TXNIP promoter, which contains a carbohydrate response element (ChoRE), is regulated by
transcription factors MondoA:Max-like protein X (MLx), nuclear factor Y (NF-Y), and the carbohydrate
response element-binding protein (ChREBP) [45]. Transcription factors forkhead box O1 (FOXO1) and
FOXO3a can bind to the TXNIP promoter and by competing with ChREBP can downregulate TXNIP
transcription [46,47]. Activation of AMP protein kinase (AMPK) can also lead to inhibition of TXNIP
mRNA transcription [48].
The mechanism whereby TXNIP expression is induced through the activation of the receptor for
advanced glycation endproducts (RAGE) by the RAGE ligand S100b is of relevance for th consideration
of AD as RAGE is a receptor for Aβ and is involved in Aβ toxicity and AD pathogenesis [58]. It was
demonstrated in Schwann cells in vitro and injured sciatic nerve in vivo that binding of S100b to RAGE
induced TXNIP with TXNIP being involved in the downstream activation of p38 mitogen-activated
protein kinase (MAPK), cAMP response element-binding protein (CREB), and nuclear factor κB (NFκB).
RAGE silencing blocked the induction of TXNIP, whereas the silencing of TXNIP inhibited the activation
Int. J. Mol. Sci. 2020, 21, 9357 4 of 24
of these signaling pathways, preventing RAGE-induced fibronectin and IL1β synthesis and Schwann
cell migration [58]. Induction of TXNIP by RAGE ligands in retinal endothelial cells through the
activation of p38 MAPK and NFκB also led to enhanced expression of inflammation-associated genes,
including cyclooxygenase 2 (Cox2), vascular endothelial growth factor (VEGFA), and intercellular
adhesion molecule-1 (ICAM1). Expression of these genes was reduced when TXNIP expression was
inhibited, and enhanced with TXNIP overexpression [60].
3.1. Cell Types
TXNIP expression has been studied in a range of different cell types derived from different tissues.
Expression of TXNIP is not tissue-specific, with TXNIP RNA being detected across all tissues and many
different cell types. The highest expression levels were demonstrated in the lungs, thyroid glands,
adipose tissue, skeletal muscle, and blood mononuclear cells (https://www.proteinatlas.org/ENSG00000
265972-TXNIP/summary/rna). By comparison, expression in neural tissue was relatively low, with the
highest levels in the retina. The highest levels of constitutive expression of TXNIP mRNA were in
muscle-derived cell lines (https://www.proteinatlas.org/ENSG00000265972-TXNIP/summary/rna).
A common feature of all expressing cell types has been the induction of TXNIP by different
forms of cellular stress. Increased levels of palmitate and other lipids that led to cellular endoplasmic
reticulum (ER) stress [61,62], increased levels of N-methyl D-aspartate (NMDA) resulting in NMDA
receptor activation, and increased cellular calcium [63], increased ischemia/hypoxia, and increased
glucose, resulting in enhanced oxidative stress, which all induced TXNIP expression. Increased levels
of ROS from dysfunctional mitochondria can also increase TXNIP expression [32].
The promoter for VDUP1/TXNIP contains many different cis-regulatory sequences, but the presence
of the heat shock factor element (HSE) sequence appeared critical for controlling cellular responses
to certain stresses [51]. Using HEK-293 human embryonic kidney-derived Bosc cells, TXNIP was
upregulated when cells were grown at high density or with serum deprivation, but this effect was
abolished if the HSE sequence was deleted from the promoter. Overexpression of heat shock factor
(HSF) in these cells upregulated the expression of TXNIP [51]. Many different stress factors have been
shown to induce TXNIP expression in different cell types. One common factor can be ER stress. In an
experimental cell model using INS-1 rat islet-derived cells, the induction of unfolded protein response
(UPR) due to thapsigargin-induced ER stress resulted in the rapid induction of TXNIP expression
along with the UPR sensor molecules Inositol-requiring transmembrane kinase/endoribonuclease
1α (IRE1α) and protein kinase RNA-like ER kinase (PERK). In cells deficient in IRE1α and PERK,
an ER stress-induced increase in TXNIP did not occur. Activated IRE1α increased TXNIP mRNA
stability by reducing levels of a TXNIP-destabilizing microRNA, miR-17. As a result of elevated
TXNIP protein expression, NLRP3 becomes activated, resulting in the formation of caspase-1 and
bioactive IL-1β [50]. This mechanism is believed to be a key event in diabetes, as excess TXNIP leads to
pancreatic cell death, whereas knockdown of TXNIP prevented ER stress-induced cell death [64]. It has
been previously shown that excess glucose-induced TXNIP expression by activating the transcription
factor carbohydrate response element-binding protein (ChREBP) causes binding to an element in the
TXNIP promoter and increasing transcription [65]. Activation of ChREBP and translocation to the
nucleus also occurred as a result of ER stress [64]. The described mechanism for the ER stress-induced
unfolded protein response (UPR) could have direct relevance for neurodegenerative diseases such
as AD and Parkinson’s disease (PD) where accumulations of toxic Aβ or α-synuclein, primarily
produced by neurons, can induce UPR [66,67]. Other transcription factors can positively or negatively
affect the expression of TXNIP. Overexpression of transcription factor Ets-1, which is activated by
inflammatory/oxidative stress associated extracellular regulated kinase (ERK1/2), resulted in increased
TXNIP in Min6 β-cells and mouse islet cells. Knockdown of Ets1 reduced the expression of TXNIP.
Overexpression of Ets and TXNIP negatively affected cellular proliferation and glucose regulatory
functions [68].
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3.1.1. Peripheral Cells
Many studies of TXNIP cellular expression in peripheral cells have focused on pancreatic
islet cells in terms of effects on glucose uptake and metabolism, insulin secretion, and cell death.
These studies have been extensively reviewed for their significance in understanding mechanisms
of diabetes (for recent reviews, see [69,70]). For this review focusing on brain diseases with
inflammatory components, we will consider TXNIP expression in macrophages and its consequences
on inflammation. Increasing TXNIP expression in human blood-derived macrophages with a
peroxisome proliferator-activated receptor-gamma (PPAR-γ) agonist resulted in enhanced levels
of activated caspase-3, indicative of inflammasome activation, and also increased apoptosis [71].
In contrast, stimulating macrophages with a PPAR-alpha agonist resulted in increased TRX and
reduced the expression of TXNIP, reduced caspase-3 activation, and reduced numbers of apoptotic
cells [72]. Induction of TXNIP in RAW264 murine macrophage cells with the sugar D-allose or
by plasmid-mediated overexpression inhibited the differentiation of osteoclasts by inhibiting the
transcriptional activity of activator protein 1, NFκB, and nuclear factor of activated T cells (NFAT) [73].
Earlier studies have identified D-allose to have significant antiproliferative properties in several types
of cancer cells [74–76] through the activation of the transcription factor MondoA:Mlx and the induction
of TXNIP expression [77].
TXNIP deficiency due to treatment with lipopolysaccharide (LPS) used as a model of endotoxic
shock can exacerbate inflammation. Macrophages from TXNIP-deficient mice produced increased
amounts of nitric oxide in response to LPS treatment, and in vivo, TXNIP-deficient mice were rescued
from endotoxic-shock-induced death by a nitric oxide synthase inhibitor. The mechanism is due to
the LPS inhibition of MondoA:Mlx activation preventing the induction of TXNIP expression [78,79].
In contrast to LPS, chemicals that induce endoplasmic reticulum (ER) stress in macrophages, including
tunicamycin, produced enhanced inflammation through increased production of ROS causing TXNIP
induction NFκB activation and inflammasome/caspase-1 activation resulting in enhanced IL-1β
secretion [80].
3.1.2. Neurons
The first study describing TXNIP function in neural cells employed cerebellar granular neurons,
which underwent apoptosis when culture conditions were switched from high potassium depolarizing
conditions to physiological potassium conditions. TXNIP expression was significantly enhanced in
neurons under this and other apoptosis-inducing conditions. TXNIP induction was inhibited by
increased calcium influx through voltage-dependent calcium channels [57]. Glutamate neurotoxicity
was shown to be dependent on TXNIP inflammasome activation. Treatment of mice hippocampal slice
cultures or SH-SY5Y cells with toxic doses of glutamate resulted in increased ROS, ER stress, increased
TXNIP expression, and NLRP3 inflammasome activation, resulting in cell toxicity [81]. Treatment with
the antioxidant curcumin was protective by the activation of AMPK and reducing the activation of
IRE1α and PERK, resulting in the decreased expression of TXNIP, reduced NLRP3 inflammasome
activation, and reduced cell death. Curcumin increased AMPK activity, whereas knockdown of
AMPKα with specific siRNA abrogated its inhibitory effects. The protective effects of curcumin on
inhibiting phosphorylated (p)-IRE1α, p-PERK, and NLRP3 expression in the hippocampus CA1 region
was also demonstrated in vivo in rats subjected to hypoxia/ischemia insults [81]. A recent study that
characterized the gene expression profiling of SH-SY5Y-derived neurons stably overexpressing the
mitochondria-localized antioxidant protein mitochondrial ferritin (FtMt) demonstrated significantly
reduced constitutive levels of expression of TXNIP mRNA. As increased FtMt will reduce ROS produced
by mitochondria, this finding demonstrated a link between mitochondria and TXNIP expression in
neurons [82]. Over-expression of FtMt and reduced TXNIP was protective for these cells.
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3.1.3. Microglia
The interaction of ROS/oxidative stress and inflammasome activation can be demonstrated
in microglia, the major mediator of innate inflammatory responses in the brain. Microglia treated
with thrombin, a factor involved in brain injury after infarct or hemorrhage, expressed increased
amounts of ROS and TXNIP, causing inflammasome activation and apoptosis. Treatment with
N-acetyl cysteine, a free-radical scavenger, prevented TXNIP induction, resulting in cell death [83].
Resveratrol, a polyphenol with antioxidant, sirtuin, and PPAR-γ-activating properties, inhibited
Aβ-induced inflammatory activation and proliferation of microglia by inhibiting the activation of
TXNIP/TRX/NLRP3 inflammasome pathway [84]. As a model of chronic stress, treatment of primary
mouse microglia with the stress hormone corticosterone increased TXNIP expression, TXNIP/NLRP3
interactions, and IL-1β levels, indicating inflammatory activation [85]. Knocking-down TXNIP
expression significantly inhibited corticosterone-induced inflammatory activation. Similar findings
were shown in mouse brains of corticosterone-treated animals [85].
A recent RNA sequencing profiling study of microglia purified from AD model mice identified
the decreased expression of TXNIP between microglia considered homeostatic and microglia activated
to a stage 1 disease-associated microglia (DAM) [86,87]. Similarly, a number of homeostatic microglial
genes (P2ry12, P2ry13, Tmem119, Cxcr1) were also downregulated between these groups. DAM is a
newly defined phenotype describing activated plaque-associated microglia with the function to reduce
the amplification of inflammation.
3.1.4. Astrocytes
Astrocytes, the major support cells of the central nervous system providing growth factors,
metabolic support, and detoxifying potentially damaging molecules (e.g., glutamate), can become
activated by inflammatory cytokines and contribute to neurodegenerative processes by increased ROS
and nitric oxide production. In a rat model of obesity, high-fat diet (HFD)-fed rats, both wild-type
and spontaneously hypertensive rats, had evidence of abnormal capillary formation and degeneration
along with the enhanced expression of TXNIP, NFκB, and inflammatory cytokines IL-1β and TNFα [88].
Increased expression of TXNIP was detected in astrocytes, retinal endothelial cells, and some microglia.
Increased interaction of TXNIP and NLRP3 was also demonstrated in brain tissues from HFD rats. In a
model of chronic mild stress/depression, deletion of the mitochondrial uncoupling protein-2 resulted
in enhanced oxidative stress, enhanced TXNIP expression, and NLRP3 inflammasome activation in
astrocytes [89]. In a rat model of subarachnoid hemorrhage, the peak induction of TXNIP correlated
with the peak of cell death. Inhibition of TXNIP expression and the use of ER stress inhibitors
resulted in an insignificant reduction of cell death. TXNIP expression was detected in astrocytes,
microglia, and neurons in this model [90]. The role of astrocyte TXNIP in cellular lactate and glucose
energy metabolism was demonstrated [91]. Activation of AMPK in astrocytes inhibited TXNIP by its
phosphorylation and by promoting its degradation and inhibition of transcription. Activation of AMPK
resulted in improved levels of glut-1 transporter expression in astrocytes. In AMPK astrocyte-specific
deletion mice, glucose and lactate metabolism was impaired by high TXNIP expression resulting in an
energy imbalance in neurons and, consequently, and cell death [91].
3.1.5. Endothelial Cells
TXNIP is involved in vascular dysfunction due to damage to vessel endothelial cells, the major
cause of complications resulting from diabetes [92]. A number of studies have shown common
mechanisms that high glucose and high levels of oxidized low-density lipoproteins (oxLDL) result
in oxidative stress and inflammation through the enhanced expression of TXNIP and inflammasome
activation. As an example, treatment of endothelial cells with high glucose and oxLDL combined with
rosmarinic acid, an anti-inflammatory and antioxidant, inhibited TXNIP expression, inflammasome
activation, and endothelial dysfunction through the inhibition of p38 MAPK and FOXO1 signaling.
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Similar results were obtained with ROS scavengers and p38 MAPK and FOXO1 inhibitors [93].
TXNIP knockout mice were shown to be resistant to the retinal endothelial dysfunction that occurred
with a HFD in wild-type mice. The TXNIP gene deletion mice did not have the breakdown of the
blood–retinal endothelial barrier that occurred in 18-week HFD-fed wild-type mice [94]. Overexpression
of TXNIP in human aortic endothelial cells induced by high glucose or the overexpression of ChREBP
directly caused apoptosis and impaired NO function. In vivo, type-1 diabetes modeled in rats caused
increased TXNIP in peripheral blood along with decreased NO and VEGF, increased ROS, and increased
inflammation-associated vascular cell adhesion molecule 1 (VCAM-1) [95].
3.1.6. Retinal Pigment Epithelial Cells
Retinal pigment epithelial (RPE) cells are the major support cells for the photoreceptor neurons in
the eye. These cells transport nutrients, ions, and water, protect against photooxidation, reisomerization
of all-trans-retinal into 11-cis-retinal, crucial for the visual cycle, phagocytosis of damaged photoreceptor
constituents, and secrete essential factors for the structural integrity of the retina, for example
pigment epithelial-derived factor (PEDF). These cells are damaged by the high-glucose/oxidative
stress consequences of diabetes [96], and their dysfunction is involved in the development of
diabetic retinopathy [97]. High-glucose-induced TXNIP in RPE cells resulted in mitochondrial
depolarization, mitochondrial fragmentation, and shuttling to lysosomes. TXNIP overexpressing RPE
cells showed significant changes in lysosome structure and autophagy. These high-glucose effects were
inhibited if TXNIP expression was suppressed [98]. Surprisingly, another study demonstrated that
the downregulation of TXNIP by oxidative stress in the RPE cell line ARPE-19 resulted in reduced
cellular proliferation. The consequences of downregulation of TXNIP were increased autophagic flux,
and increased p53 activation resulting in AMPK activation. The consequences of these were reduced
blood–retinal barrier integrity [99].
3.1.7. Brain Cancer Cells
Overexpression of TXNIP has been correlated with inhibition of tumor cell suppression in multiple
studies. In addition, alterations in the expression of all proteins of the TRX system, including TRX,
TRX reductase (TRXR), and TXNIP, in gliomas and glioblastomas were associated with differing clinical
outcomes. High cytoplasmic TRXR and TRX expression in patients with high-grade gliomas was
associated with poor outcomes, whereas in medulloblastoma, high expression of cytoplasmic TRXR,
TRX, and nuclear TRX was associated with worse prognosis [100]. In similar studies of malignant glioma,
higher TXNIP expression levels were associated with extended patient survival time [24]. In vitro
analysis in U251 cells showed increased growth, migration, and invasion with downregulated TXNIP
expression compared with their non-transfected counterparts. Although not studied in brain cancer
cells, it was shown in thyroid cancer cells that TXNIP overexpression resulted in decreased glucose
uptake and cell division. In a mouse model, transplanted TXNIP-overexpressing cells had reduced
metastatic potential [101]. A similar feature was observed in prostate cancer cells. Overexpression
of TXNIP in a prostate cancer cell line blocked cell proliferation and glucose uptake. Cell division
became halted in the G0/G1 phase, which promoted cell apoptosis [11]. This study also showed in a
large series of human prostate benign hyperplasia and cancer samples that there was significantly less
TXNIP expression in the cancer samples. Levels of TXNIP in these samples negatively correlated with
the expression of glucose transporter (glut1)-1 mRNA [11].
4. TXNIP, Hyperglycemia, and Oxidative Stress—NLRP3 Inflammasome Complex
Presentations of research data on TXNIP in relation to disease have frequently considered
TXNIP/TRX interactions and the resulting oxidative stress as a separate mechanism from its role in
the NLRP3 inflammasome activation, but these two features are interrelated. Although associated
with enhanced inflammation, NLRP3 inflammasome activation occurs in all brain cell types, including
neurons, astrocytes, and endothelial cells, not just microglia [81,102]. If one considers the events
Int. J. Mol. Sci. 2020, 21, 9357 8 of 24
occurring under hyperglycemic conditions, excess glucose leads to increased levels of ROS by
inducing the overproduction of NADH and increased mitochondrial-derived ROS that inhibits
GAPDH, the enzyme that removes excess cellular glucose [103]. However, this inhibition that activates
alternative glucose metabolic pathways leads to further ROS production. Excess ROS directly induces
the expression of TXNIP and the inflammation-associated transcription factor NFκB. Excess TXNIP
will further exacerbate oxidative stress by binding TRX and, in cooperation with NFκB, bind and
activate the inflammasome complex. The inflammasome complex consists of an association of
NLRP3, apoptosis-associated speck-like protein containing a caspase-binding domain (ASC) and
pro-caspase-1 [104,105]. In the presence of excess ROS, TXNIP interaction with TRX can be reversed,
which then allows released TXNIP to bind and activate NLRP3 inflammasome, resulting in enhanced
inflammation. Activation of NLRP3-inflammasome promotes the formation of activated caspase-1,
which processes interleukin (IL)-1β, IL-18, and IL-33 into bioactive forms [106], and also induces cell
death through pyroptosis [107]. An earlier study also demonstrated that inflammasome activators
such as uric acid crystals induced the dissociation of TXNIP from TRX in the presence of ROS, allowing
it to bind and activate the NLRP3 complex and enhance caspase activation [50].
5. TXNIP Expression in the Brain
Studies focusing on the cellular distribution of TXNIP in brain cells are limited. Detailed
immunochemical characterization of TXNIP/VDUP1 by comparing its distribution in Drosophila
and rat brains showed relatively conserved patterns of expression. The antibodies employed
in this study identified this protein in both of these species. Constitutive expression in subsets
of neurons and astrocytes were identified using double immunohistochemistry staining with
appropriate markers. This study did not report the constitutive microglial expression of TXNIP
but observed nuclear immunoreactivity under hyperglycemic conditions [108]. A further study
employed immunohistochemistry to compare the neuroanatomical distribution of different TRXs,
TRRs, glutathione/glutaredoxin, peroxiredoxins, and TXNIP in rat brains. Expression of these
antioxidants and related molecules was highest in brain regions susceptible to damage in conditions of
hypoxia/ischemia including the cerebellum, cortex, hippocampus, substantia nigra, striatum, and spinal
cord. Weak expression of TXNIP was detected in subsets of neurons, not glia, in these brain regions,
except the spinal cord, and with the highest expression in the retina. The pattern of expression of TRX1
and TXNIP showed extensive overlap [109]. A direct link between metabolic activity and TXNIP was
demonstrated in mice with the expression of TXNIP in medial hypothalamic neurons, which increased
under conditions of nutrient excess and obesity [110]. A further study using directed TXNIP gene
deletion and overexpression in Agrp hypothalamic neurons showed that the overexpression of TXNIP
led to reduced energy expenditure and activity, resulting in obesity and fat accumulations, whereas
the deletion of TXNIP in Agrp neurons had a reverse effect, with increased energy metabolism and
activity [111]. Another study showed strong induction of TXNIP in the hypothalamus of mice in a state
of lowered energy metabolism, though increased TXNIP expression was detected in ependymal-lining
cells, not neurons, in the hypothalamus. Increased TXNIP expression was also detected in the liver and
adipose tissues of these animals [112]. These studies highlighted physiological functions for TXNIP in
regulating energy metabolism.
5.1. TXNIP in Acute Neurological Conditions
The role of TXNIP in ischemic stroke disease using animal models has been examined. Wild-type,
TXNIP knockout, and wild-type mice treated with the TXNIP inhibitor resveratrol were subjected to
middle cerebral artery occlusion (MCAO) to model ischemic stroke. These studies showed TXNIP
knockout, and resveratrol-treated mice had an approximately 40% decrease in infarct size and
significantly improved neurological scores. This improvement correlated with reduced oxidative stress
and reduced evidence of NLRP3 inflammasome activation [113]. A similar model using rats subjected
to MCAO with reperfusion was significantly protected by treatment with umbelliferone, an antioxidant.
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This protection occurred as treatment increased the expression of PPAR-γ, which resulted in reduced
NLRP3 inflammasome activation due to the inhibition of TXNIP expression [114]. A recent study
utilized neonatal rat pups subjected to common carotid artery ligand and hypoxia to induce ischemic
injury [113]. Animals treated with a PPAR-β/δ agonist had a significantly reduced infarct area and
improved neurological features. This study showed that PPAR-β/δ activation induced the expression
of miRNA miR17-5p, which reduced TXNIP levels and the activation of Apoptosis signal-regulating
kinase 1 (ASK1) and p38 MAPK [115]. Promoting TXNIP activation in vivo using a TXNIP CRISPR
activation plasmid reversed the protective effects, as did the administration of a PPAR-β/δ antagonist.
The consequence of PPAR-β/δ activation by GW0742 was decreased TXNIP, NLRP3, IL-6, and TNF-α
and reduced numbers of activated microglia [116]. Similar results from PPAR activation were observed
in vitro using PC12 neuronal-like cells subjected to oxygen/glucose deprivation (OGD) [116].
A recent study employing a rat model for cerebral venous sinus thrombosis demonstrated that
neuronal pyroptosis was caused by endoplasmic reticulum stress and oxidative stress that activated
the TXNIP/peroxynitrite/NLRP3 inflammasome pathway. Immunohistochemical staining revealed
that increased TXNIP was primarily in neurons and also in subsets of microglia and astrocytes [117].
TXNIP immunoreactivity is colocalized with p-IREα1 and p-PERK, mainly in neurons. Time-course
studies showed maximal induction of TXNIP occurred three days after surgery and then expression
declined. The same time course of induction was observed for NLRP3, whose expression was in
neurons and microglia. Direct interaction of TXNIP and NLRP3 at three days was demonstrated
by immunoprecipitation and immunoblot analysis, producing results indicative of inflammasome
activation [117], and at three days, IL-1β levels were also at their highest. A significant feature of this
study was the decline of TXNIP and NLRP3 levels after reaching maximal levels. This suggests that
the time for the increased expression of these proteins will be restricted and limited to ongoing active
sites of pathology.
5.2. TXNIP in Neurodegenerative Diseases (Animal and Cellular Models)
TXNIP has been implicated in neurodegenerative diseases, but there have only been a limited
number of studies on this topic. Figure 1 illustrates the potential interacting features of TXNIP in the
progression of AD. Similar processes could occur in Parkinson’s disease (PD). This is a hypothetical
model as further human-focused studies of brain expression of TXNIP are needed. Overexpression
of α-synuclein, the protein implicated in the pathogenesis of PD, in transgenic mice or transfected
HEK cells, produced increased levels of TXNIP [118]. In this study, it was also shown that the
overexpression of TXNIP resulted in the enhanced accumulation of α-synuclein. This resulted in
increased accumulation of the autophagy proteins LC3-II and p62, indicating excess TXNIP caused a
blockade of autophagic flux. TXNIP impaired lysosomal function by downregulating the expression
of the lysosomal membrane protein ATP13A2. Overexpression of TXNIP by the injection of a viral
transduction vector into mice substantia nigra pars compacta resulted in a 38% decrease in the
numbers of tyrosine-hydroxylase-positive neurons [118]. This was the first study linking TXNIP to PD
pathogenesis, but there have been no studies on human brain tissues. The only study to date examining
TXNIP expression in human AD and control brains observed an increased expression of TXNIP
mRNA and protein in AD cases and increased TXNIP immunoreactivity of cells associated with Aβ
plaques and phosphorylated tau (p-Tau)-positive structures. The identities of TXNIP-immunopositive
cells were not confirmed but the authors implied that they were microglia due to their morphology
as other components of the NLRP3 inflammasome complex and IL-1β levels were increased [26].
An experimental study using APP/PS1 plaque-developing transgenic mice demonstrated that TXNIP
protein levels were significantly elevated whereas TRX levels were not in these mice at 9 and 12 months
of age when Aβ deposits had developed compared to wild-type mice. The treatment of murine
primary cortical neurons or HT22-derived hippocampal neurons with oligomeric Aβ (1-42) produced
a significantly increased expression of TXNIP but not TRX [119]. Inhibiting TXNIP expression in
Aβ-treated cells resulted in reduced amounts of oxidative modifications of cellular proteins. Wild-type
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mice treated with a regime of chronic unpredictable stress over 28 days had increased levels of TXNIP,
but not TRX, protein in the frontal cortex and hippocampus. The consequence of this was evidenced
by increased levels of cysteine oxidative modifications, such as increased protein sulfenylation and
nitrosylation and increased amounts of phosphorylated (activated) ASK1 [120]. Another study showed
increased levels of TXNIP and decreased levels of TRX in the hippocampus of the female 5xFAD line
of amyloid plaque-developing mice. Using the SH-SY5Y neuroblastoma cell line, this study showed
that estradiol could protect from TXNIP induction and cell toxicity induced by in vitro Aβ (1-42)
treatment. The basis of this study was the analysis of human gene expression profiling data that
showed significantly higher levels of TXNIP mRNA in samples from female AD compared to male AD
subjects [121]. The effect of estradiol modulation of TXNIP upregulation was through the activation of
AMPK. Using the 3xTg-AD mouse model, significantly enhanced TXNIP was detected in the cortex but
coincident with significantly reduced expression in the spleen compared to wild-type mice. The mean
spleen weight of 3xTg-AD mice at 17 months was three times that of wild-type mice, whereas levels of
spleen TXNIP in 3xTg-AD mice was only approximately 5% of wild-type levels. The enhanced cerebrum
TXNIP expression was associated with increased histone acetylation, increased transcription factor
CCCTC-binding factor (CTCF) binding, and TXNIP promoter hypomethylation, whereas the reduced
spleen TXNIP expression was associated with increased histone methylation, reduced CTCF binding,
and TXNIP promoter hypermethylation. Increased cortical expression of TXNIP was detectable at
seven months before increased levels of p-Tau and inflammatory mediators became significant. It was
concluded that the interaction of the brain and peripheral TXNIP contributed to cognitive decline,
but identifying mechanisms will require further study [122]. The relationship of TXNIP and enhanced
tau phosphorylation was investigated in 5xFAD mice and SH-SY5Y neuroblastoma cells. Treatment of
SH-SY5Y cells with Aβ (1-42) resulted in TXNIP overexpression, followed by enhanced oxidative stress,
p38 MAPK, and increased tau phosphorylation at Ser202/Thr205. Knockdown of TXNIP significantly
reduced TXNIP expression and tau phosphorylation in SH-SY5Y cells, whereas the treatment of
5xFAD mice with the voltage-dependent calcium channel blocker verapamil had similar effects [123].
A consensus on how TXNIP could be involved in AD-type degenerative processes is still lacking.
Figure 1. Overview of features of TXNIP expression and function that might contribute to AD
pathogenesis. Multiple factors have been identified to be possible initiators of AD-related neurotoxicity,
all of which have been shown to induce TXNIP. The potential interactions leading to enhanced
inflammation and neurodegeneration are illustrated. ROS: reactive oxygen species, HiGl: High glucose,
ER: endoplasmic reticulum, TXNIP: thioredoxin-interacting protein, TRX: thioredoxin, IL: interleukin.
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A separate series of studies identified features of NLRP3 inflammasome activation related to
enhanced inflammation associated with AD pathology in human AD brains and mouse models [124–127].
These studies did not examine the involvement of TXNIP in the features of inflammasome activation,
but it can be deduced based on other studies that it is involved in the observed pathological changes.
It was shown that there was increased caspase-1 activation in AD and MCI human brains. In mice
with genetic deficiencies of NLRP3, microglia showed a smaller inflammatory response and increased
phagocytosis of amyloid beta [124]. It was shown in AD plaque-developing mice that injection of
brain-derived ASC specks produced upon inflammasome activation promoted the seeding of Aβ
plaques in brains [128].
Alterations in the expression of TXNIP have also been identified in blood cells from patients
with multiple sclerosis (MS), a degenerative disease of white matter associated with autoimmune
responses to myelin. In patients with newly diagnosed MS, for those receiving interferon or other
immunosuppressive therapies, TXNIP mRNA expression was decreased whereas TRX1 mRNA
was significantly increased. This suggested a disturbance in oxidative stress as part of the disease
pathology [129].
5.3. Linking Diabetes, TXNIP, and Alzheimer’s Disease: Hypothesis
The role of TXNIP in inducing pancreatic cell death and causing type-1 diabetes appears to
depend on properties not directly or exclusively related to its binding of TRX. A mutant form of
TXNIP that does not bind TRX was shown to maintain glucose uptake inhibition properties, which was
a property of the α-arrestin domain [130]. Subsequent studies identified that TXNIP inhibited the
expression of glucose transporter-1 (Glut-1) and promoted endocytosis of the protein from the plasma
membrane [131]. Activation of AMPK under conditions of energy stress phosphorylated TXNIP
and promoted its degradation, preventing interactions with Glut-1 on the plasma membrane and
restoring cellular glucose uptake and metabolism [131]. TXNIP also inhibits glucose uptake due to
inhibiting glycolysis and oxidative phosphorylation. Cells lacking TXNIP showed increased glucose
uptake [131]. How these features might be involved in AD is unclear but can be suggested based on
glucose hypometabolism, a well-established feature of AD [132]. Glut-1 is highly expressed in the
brain, particularly by cerebrovascular endothelial cells and astrocytes, whereas Glut-3 is the major
neuronal transporter of glucose [133].
Figure 2 illustrates the potential involvement of peripheral TXNIP in modulating cerebral glucose
metabolism in the brain and AD, contributing to neurodegeneration. As several studies have shown
that the neuronal expression of TXNIP is more commonly observed under stress/injury conditions,
further experimental studies to determine if TXNIP overexpression affects Glut-3 expression and
localization are needed. The concept of how AD neurodegeneration could be linked to diabetes,
deficits in insulin signaling and glucose metabolism, and endothelial dysfunction should be considered.
The term type-3 diabetes has been used to describe the lack of response of neurons to insulin and
insulin-like growth factor signaling and the consequent deficits in glucose metabolism [134]. There have
been epidemiological data suggesting patients with insulin-resistant type-2 diabetes are at greater risk
of developing AD-type dementia and that antidiabetic medication was effective at reducing the risk of
AD [135], though these findings have not been extensively confirmed. Examining the neuropathological
records from an autopsy series, there was no significant correlation between type-2 diabetes and the
severity of plaque and tangle load in brain regions affected by AD [136], with the exception of subjects
with an apolipoprotein E4 allele. It was confirmed in a more recent study that type-2 diabetes did
not correlate with the amyloid plaque or neurofibrillary tangle load, but it was commented on that
both diseases are associated at early stages with a significant cerebrovascular disease that can affect
the development of AD pathology [27]. Much interest in this topic has been on whether patients
treated with the insulin sensitizer metformin have a reduced risk of dementia [137–139]. Metformin,
which activates AMPK leading to inhibition of TXNIP expression, has significant activity in inhibiting
the activation of the NLRP3 inflammasome complex [140–142]. Metformin also inhibited the interaction
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of TXNIP and NLRP3 [143]. Further studies are needed on human brains from cases with diabetes to
determine whether there is increased expression of TXNIP and whether this is correlated with AD or
severity of AD pathology.
Figure 2. Potential peripheral–CNS interactions involving TXNIP in glucose metabolism in the brain.
6. Physiological Consequences of Loss of TXNIP
6.1. Experimental Animals
A number of studies have reported the phenotypes of mice constructed to have total TXNIP
gene deletion. The consequences of this have been both beneficial and detrimental depending
on the disease model. In an initial report, the cause of hyperlipidemia in a mutant mouse strain
(Hcb-19) was a mutation in the Txnip gene resulting in reduced expression. These mutant mice
had hypertriglyceridemia, hypercholesterolemia, elevated plasma apolipoprotein B, and increased
secretion of triglyceride-rich lipoproteins with increased ketone body synthesis [144]. In a TXNIP
gene-deleted mouse model, they developed significantly increased fatty liver, with high levels of
triacylglycerol, cholesterol ester, and total cholesterol, with higher-serum non-esterified fatty acids.
Elevated fatty acid synthesis was the primary cause of liver lipogenesis in TXNIP knockout mice [145].
Gene deletion of TXNIP also resulted in impaired immunity with reduced numbers of natural killer
cells and the impaired dendritic cell maturation of T cells [146–148]. TXNIP gene deletion can lead to
lethality under fasting conditions due to a switch in metabolism to hyperlipidemia and hypoglycemia.
Under these conditions, mice experienced enhanced glucose-induced insulin sensitivity and secretion
and an increased expression of PPAR-target genes [149]. TXNIP gene-deletion mice fed a high-fat
diet developed significantly greater fat deposits and body mass but with increased insulin sensitivity.
This study correlated the loss of TXNIP with the augmented activation of PPAR-γ [150]. These effects
on enhanced hyperlipidemia due to TXNIP gene deletion were detrimental to the affected organisms,
but beneficial outcomes upon reversing the consequences of diabetes/hyperglycemia were also observed.
Knockdown of TXNIP in vitro protected mesangial cells grown under high-glucose conditions from
apoptosis and ASK1 and p38 MAP kinase signaling [151,152]. In wild-type and TXNIP knockout
mice rendered diabetic with streptozotocin, the TXNIP knockout mice showed significant protection
from diabetic nephropathy. The knockout diabetic mice did not show increased thickening of the
basal membrane or increased glomerular TGF-β1, collagen IV, and fibrosis was seen in the wild-type
mice [153]. Loss of TXNIP provided significant protection in mice fed a HFD, showing significant
protection from retinal degeneration and microvascular dysfunction due to reduced activation by the
retinal endothelial cells of TXNIP/NLRP3 inflammasome [94]. TXNIP gene-deletion mice have been
shown in general to be protected from the vascular consequences of high-fat/obesity or high-sugar diets
compared to wild-type mice. In a model that studied the consequence of HFD and TXNIP gene deletion,
it was shown that wild-type mice had significantly impaired blood flow and vascular density due to
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impaired angiogenesis compared to the TXNIP knockout mice. In this model, there was significantly
higher IL-1β, increased numbers of infiltrating macrophages, and increased vascular endothelial
growth factor (VEGF) expression and VEGF receptor activation in wild-type mice only. The enhanced
vascular inflammation was due to the high-fat diet activating the TXNIP/NLRP3 inflammasome,
which did not occur in TXNIP knockout mice [154].
6.2. Human Subjects
From the above-described experimental studies, the loss of TXNIP in mice has been beneficial
in reversing the consequences of hyperglycemia but with a detrimental effect on liver fatty acid
metabolism. These animals were constructed with Txnip gene deletions, but the loss of TXNIP has
been identified in rare genetic cases in human subjects. The published case report covers children of 4,
9, and 13 years of age [155]. This showed that the loss of TXNIP is nonlethal, but the affected subjects
show lactic acidosis, low-serum methionine, and impaired oxidative phosphorylation in response to
glucose and pyruvate [155]. There are no reports as yet if such individuals are resistant to diabetes or
neurodegenerative diseases. These studies demonstrate that the pharmacological lowering of TXNIP
levels is unlikely to be associated with significant side effects.
Table 1 lists the most significant studies related to the effects of TXNIP expression in the brain
or brain-derived cells. This is a subjective list based on the theme of this article and is proposed to
illustrate the different features of TXNIP in interactions with the nervous system.
Table 1. Summary of major studies of TXNIP in the brain or brain-derived cells.
Finding Reference
TXNIP induced in cerebellar granular neurons by changes in potassium led to cell death [57]
Glutamate-induced cell death in vivo and in vitro via TXNIP induced expression [81]
TXNIP expression downregulated in vitro in neuronal cells overexpressing mitochondrial ferritin [82]
TXNIP induction by Aβ in microglia resulting in activation inhibited by antioxidant resveratrol [84]
High-fat-diet fed rats had increased expression of TXNIP in astrocytes, retinal endothelial cells,
and microglia [88]
Increased TXNIP expression in a rat model of subarachnoid hemorrhage in neurons, astrocytes,
and microglia correlated with cell death, which was reduced by inhibiting TXNIP expression [156]
Increased TXNIP expression in a rat model of subarachnoid hemorrhage in neurons, astrocytes,
and microglia correlated with cell death which was reduced by inhibiting TXNIP expression [156]
Downregulation of TXNIP in RPE cell line by oxidative stress reduced cell proliferation [99]
Decreased expression of TXNIP in glioma cells correlated with poor patient outcome [100]
TXNIP was immunolocalized to neurons and microglia in normal drosophila and rat brain tissue [108]
Increased neuronal pyroptosis in a rat model of cerebral thrombosis mediated by elevated TXNIP
expression and inflammasome activation [117]
TXNIP overexpression in substantia nigra of mice caused the loss of dopaminergic neurons [118]
Increased expression of TXNIP mRNA, protein, and numbers of immunopositive cells in
AD brain [26]
Increased TXNIP expression in the brain of an AD mouse model but reduced expression in
the spleen [122]
7. Modulating TXNIP Expression
A number of different classes of agents can modulate TXNIP expression, including PPAR-γ agonists,
which include classes of drugs with insulin-sensitizing properties used for treating diabetes [157].
There have been conflicting results on the interactions of PPAR-γ and TXNIP. One study using
human kidney proximal tubule cells showed PPAR-γ agonists attenuated high-glucose-mediated
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TXNIP expression [158], whereas another using human macrophages showed that the PPAR-γ agonist
GW929 enhanced TXNIP expression [71]. Using a rat insulinoma cell line INS-1E to represent
pancreatic beta cells, it was shown that hyperglycemia activated TXNIP expression and inhibited
the activation of AMPK. Activation of AMPK with metformin or aminoimidazole-carboxamide
ribonucleotide (AICAR) reduced TXNIP expression, an effect also observed when cells were treated
with the lipid palmitate [142]. AMPK activation inhibited glucose-stimulated ChREBP nuclear entry
and binding to the TXNIP promoter, thereby inhibiting TXNIP mRNA expression. These investigators
also demonstrated that the addition of insulin to high-glucose-treated INS-1E cells reduced TXNIP
expression and prevented high-glucose-mediated apoptosis. Treatment of cells with nitric oxide (NO)
stimulated insulin secretion and reduced the expression of TXNIP; this effect was reversed when cells
were treated with a nitric oxide synthase inhibitor [159]. A recent study showed that insulin-like
growth factor-1 (IGF-1) negatively regulated TXNIP expression in vitro and in vivo. Furthermore,
this study demonstrated that oxidative stress and glucose-induced TXNIP expression could be reversed
by the administration of IGF-1 [160]. The calcium channel blocker verapamil, which is in widespread
clinical use for hypertension, has been demonstrated to significantly inhibit TXNIP expression with
therapeutic benefits. In an animal model of diabetic cardiomyopathy, three weeks of treatment with
verapamil had a significant therapeutic benefit, which correlated with the reduced expression of
TXNIP in cardiomyocytes [161]. The mechanism of action of verapamil appeared to be mediated by
the enhanced activation of the transcription repressor nuclear factor Y (NPY) [162]. As mentioned
above, verapamil was also effective in inhibiting tau phosphorylation in vivo in 5xFAD AD model
mice, inhibiting Aβ-induced tau phosphorylation in vitro, and inhibiting the expression of TXNIP and
the activation of p38 MAPK [123].
In a recent study, we identified a novel fluorinated derivative of curcumin that was highly
effective in reducing stress-induced TXNIP expression. Cellular models examined used the human
retinal pigment epithelial cell line ARPE-19, which have high constitutive levels of TXNIP expression,
and macrophages derived from the human THP-1 monocyte cell line, which have lower constitutive
expression. In this study, the effectiveness of fluorinated curcumin derivative Shiga Y6 compared
to its non-fluorinated derivative Shiga Y5 in reducing TXNIP protein and mRNA expression
under constitutive, high-glucose, endoplasmic reticulum stress, and inflammatory activation was
demonstrated [163]. This compound was also effective in inducing TRX protein and mRNA levels
in these cellular models. These studies demonstrate that derivatized curcumin molecules were
more effective than curcumin alone in lowering TXNIP expression. Other studies have shown the
effectiveness of curcumin in vitro and in vivo in inhibiting TXNIP expression but at higher doses than
we used for testing the fluorinated curcumin compound [163,164]. The effect of curcumin on TXNIP
expression appears to be through the activation of AMPK [81,165].
8. Summary
When considering the involvement of TXNIP in human acute neurological and chronic
neurodegenerative diseases, there is mostly circumstantial evidence from animal and in vitro
experiments about how it might accelerate pathology. It is clear there is a need for further detailed
studies. With regards to AD, there have been many studies on microglia and inflammation in AD
and studies showing NLRP3 inflammasome activation in AD brains without the consideration of
TXNIP ([124]). TXNIP is essential for driving NLRP3 inflammasome activation and the formation
of activated caspase-1 [50]. Preventing the interaction of TXNIP and NLRP3 will have significant
effects. This can be done by inhibiting its expression, inhibiting the stress stimuli that causes increased
expression, or manipulating the intermediate signaling pathways. As mentioned, a number of different
classes of chemicals have been identified to inhibit TXNIP expression, which might have therapeutic
potential for a number of diseases. The major issue for agents aimed at brain cells is the penetration
of the blood–brain barrier. An issue for treating elderly patients with neurodegenerative diseases is
whether inhibiting a particular target could exacerbate age-associated cancers. As decreased levels
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of TXNIP correlate with the increased growth of different types of cancer cells, this issue needs to be
considered [166].
Understanding this protein with multiple properties related to sequestering TRX1 in the cytosol,
such as sequestering TRX2 in mitochondria, modulating the expression or stability of key glucose
transporters, acting as a nuclear transcription factor, and activating inflammasome, has been
complicated. Its normal physiological function has not been elucidated. Some of the properties
are independent of the enhancement of oxidative stress due to sequestering TRX. The interaction of
oxidative stress with the activation of other properties, for example transcription factor activation,
requires further study.
From this review of the literature, there is clearly a need for further studies of TXNIP expression
in normal, aged, and disease-affected human brains. Only one study provided a limited description
of the cellular and neuroanatomical distribution of TXNIP in human brains in AD [26]. Without
this knowledge, identifying sites of TXNIP activity in relation to neuropathology, identifying the
neuroanatomical distribution and cell types mediating TXNIP activity in particular, will hinder progress
on developing TXNIP as a therapeutic target for brain diseases.
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